Table 5 Comparing bi-specific and tri-specific antibody therapy to CAR T- cell therapy
From: Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Polyspecific antibodies | CAR T- cells |
|---|---|
Polyspecific are antibodies with multiple specificities with one or more affinity sites towards tumor antigens, and another one towards an activator on immune effectors (e.g. CD3 on T cells). | T cells with genetically engineered receptors that redirect them to a chosen tumor antigen |
Highly efficient, rapid process- Created using multiple formats including advanced protein engineering and recombinant DNA technologies and administered to patients directly. Allows rapid treatment of patients | Cumbersome, boutique process- T cells from patients are collected, antigen specific receptors (CARs) are inserted invitro into T cells using viral vectors, DNA transposons, or RNA transfection and then “expanded” in the laboratory before reinfusing into lyphodepleted patient. May delay therapy for weeks. |
When activated through CD3, cytotoxic T cells inject perforin and granzyme B into target cells to kill. | When CARs bind to tumor antigen, the intracellular signaling domain is activated and the tumoricidal process by T cells is initiated. |